Korean biotech firm Alteogen Inc. has publicized the findings of their most recent Tergase® clinical study, wherein no occurrence of ADA (inclusive of neutralizing antibodies) was found.

Horizon Therapeutics Plc is a pharmaceutical organization based in Dublin, Ireland. It was founded in 2008 and has since been actively involved in the field of biomedicine.

Arcturus Therapeutics Holdings have revealed today that EMA has officially confirmed the marketing authorization application for ARCT-154.

ALK (Anaplastic Lymphoma Kinase) is a receptor tyrosine kinase that plays a crucial role in various physiological processes in the human body.

This article summarized the latest R&D progress of Succinylcholine Chloride, the Mechanism of Action for Succinylcholine Chloride, and the drug target R&D trends for Succinylcholine Chloride.

the Italfarmaco Group  has publicly declared that they have submitted a Marketing Authorization Application for Givinostat.

Genmab A/S is a biopharmaceutical company based in Hovedstaden, Denmark.

Stoke Therapeutics, Inc., reported today key points from presentations pertaining to the continued clinical research of STK-001.

This article summarized the latest R&D progress of Savolitinib, the Mechanism of Action for Savolitinib, and the drug target R&D trends for Savolitinib.

AChE inhibitors function by reversibly inhibiting AChE, leading to the accumulation of ACh at synaptic locations, which in turn improves cognitive functions in Alzheimer's disease (AD) patients.

ILiAD Biotechnologies, LLC, a biotech firm in the clinical trial phase, which is spearheading the creation of an unparalleled, progressive pertussis vaccine, reports promising preliminary results from the CHAMPION-1 clinical trial.

The therapeutic effects among the first generation of 5-HT3 receptor antagonists have no significant differences.